CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn is a biotech that has proved helpful diligently but unsuccessfully to develop a single therapy, variously named Pro 140, leronlimab, along with Vyrologix.
In development of this particular therapy, CytoDyn has cast its net wide and far both geographically and in terminology of potential indications.
CytoDyn’s inventories of leronlimab are actually building up, whether they will ever be used is actually an open question.
While CYDY has been dawdling, promote opportunities for leronlimab as a combination treatment in the treatment of multi-drug-resistant HIV happen to be closing.
I am writing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale made of my past few shares. My first CytoDyn post, “CytoDyn: What In order to Do When It’s Too Good To Be True?”, set away what follows prediction:
Instead I expect it to turn into a serial disappointer. CEO Pourhassan offered such a highly promotional picture in the Uptick Newswire employment interview which I came away with a bad impression of the company.
Irony of irony, my poor impression of the company has grown steadily, although the disappointment has not been financial. 2 years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.
What manner of stock is this that delivers a > six bagger at the moment still disappoints? Therein sits the story; permit me to explain.
CytoDyn acquired its much-storied therapy (which I shall mean as leronlimab) returned in 2012, announced as follows:
CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor of the therapy as well as prevention of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity in HIV infected subjects. Today’s transaction of $3.5 huge number of transfers ownership of the expertise as well as linked intellectual property from Progenics to CytoDyn, as well as approximately 25 million mg of majority drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 huge number of) and the very first brand new drug application endorsement ($5 million), and also royalty payments of 5 percent of net sales after commercialization.
Since that moment, CytoDyn’s guiding nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to purchase a market place cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

As opposed to having a pipeline with many therapies and multiple indications, it’s this individual treatment and a “broad pipeline of indications” because it puts it. I call some pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a potentially advantageous therapy in dozens of indications.
The opening banner of its on its website (below) shows an active company with diverse interests albeit centered on leronlimab, multiple illness types, multiple delivering presentations and multiple publications.
Can all of it be smoke and mirrors? That’s a question I have been asking myself with the very beginning of my interest in this company. Judging by way of the multiples of a huge number of several responses on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I am a lot from alone in this particular question.
CytoDyn is a traditional battleground, or some may say cult inventory. Its adherents are fiercely protective of the prospects of its, quick to label some bad opinions as scurrilous short mongering.
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News